help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
The Oncologist, Vol. 11, No. suppl_1, 34-41, September 2006; doi:10.1634/theoncologist.11-90001-34
© 2006 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jackisch, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jackisch, C.

HER-2-Positive Metastatic Breast Cancer: Optimizing Trastuzumab-Based Therapy

Christian Jackisch

Department of Gynecology and Obstetrics, Klinikum Offenbach, Offenbach, Germany

Key Words. Trastuzumab • Metastatic breast cancer • Combination therapy • Treatment beyond disease progression

Correspondence: Christian Jackisch, M.D., Klinikum Offenbach GmbH, Department of Gynecology and Obstetrics, Starkenburgring 66, D-63069 Offenbach, Germany. Telephone: 49-0-69-8405-3850; Fax: 49-0-69-8405-4456; e-mail: christian.jackisch{at}klinikum-offenbach.de

Trastuzumab with a taxane as first-line therapy is now the standard of care for patients with human epidermal growth factor receptor 2 (HER-2)-positive metastatic breast cancer (MBC). The search for additional and more effective trastuzumab-based therapies continues. Novel combinations of trastuzumab with chemotherapeutic agents, including vinorelbine, gemcitabine, and capecitabine, and hormonal therapy agents, such as tamoxifen and aromatase inhibitors, are currently under investigation in clinical trials. Available data suggest these combinations will provide additional treatment options that may ultimately lead to better outcomes for patients with HER-2-positive MBC. Evidence is growing for the use of trastuzumab treatment beyond disease progression and retreatment after (neo)adjuvant relapse is being explored to assist in clinical decision making. Already, the use of trastuzumab in the metastatic setting has changed HER-2-positive status from a marker of poor prognosis to one of better overall outcome, and ongoing studies should expand further the treatment options for patients with HER-2-positive MBC.




This article has been cited by other articles:


Home page
 Am J Health Syst PharmHome page
B. Paul, J. A. Trovato, and J. Thompson
Lapatinib: A dual tyrosine kinase inhibitor for metastatic breast cancer
Am. J. Health Syst. Pharm., September 15, 2008; 65(18): 1703 - 1710.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Harputluoglu and K. Altundag
How can we use anthracylines in the management of newly diagnosed metastatic breast cancer patients overexpressing HER-2?
Ann. Onc., June 1, 2008; 19(6): 1203 - 1203.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
M. W.L. Teng, J. A. Westwood, P. K. Darcy, J. Sharkey, M. Tsuji, R. W. Franck, S. A. Porcelli, G. S. Besra, K. Takeda, H. Yagita, et al.
Combined Natural Killer T-Cell Based Immunotherapy Eradicates Established Tumors in Mice
Cancer Res., August 1, 2007; 67(15): 7495 - 7504.
[Abstract] [Full Text] [PDF]


HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2006 by AlphaMed Press.